Pneuma Respiratory and Leads Biolabs Partnership

Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an exclusive license to develop Leads Biolabs’ panel of immuno-oncology monoclonal antibodies and fusion protein molecules for the pulmonary delivery of Leads’ antibodies and molecules.  Using Pneuma’s digital inhaler platform, the agreement provides access to the untapped potential of pulmonary delivery of Leads’ immuno-oncology therapies in the treatment of oncologic or immune-mediated lung diseases.

In a recent publication, Pneuma announced the completion of a study demonstrating the feasibility of antibody delivery to the lungs via its digital inhaler platform.  This study, conducted in an animal model, indicates that the Pneuma digital inhaler platform may provide a method for the pulmonary delivery of monoclonal antibody therapies, enabling the targeted treatment of oncologic or immune-mediated lung diseases.

“This collaboration is an exciting development for the field of immuno-oncology,” said Ronald Bukowski, MD, physician emeritus, Cleveland Clinic Foundation.  “Approaches utilizing the regional administration of novel checkpoint inhibitors may provide new treatment opportunities for patients with a variety of malignancies.”

“We are pleased to enter into a license agreement for Leads Biolabs monoclonal antibody portfolio,” said Pneuma Chief Executive Officer and co-founder Eric Hunter. “We look forward to working with their team to conduct studies that may lead to positive change in the future treatment of non-small cell lung cancer.”

Dr. Xiaoqiang Kang, Chairman and CEO of Leads Biolabs, said: “We are very excited to have this license agreement with Pneuma Respiratory. The commitment by a leader in digital pulmonary delivery of drugs is an endorsement of the value of our portfolio. We believe that Pneuma’s digital inhaler technology combined with our antibody drugs will create very exciting new opportunities for both companies. We look forward to working with Pneuma to move our candidates into the clinic as quickly as possible.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

Santa Casa Hospital System Chooses Carestream for a Unified Diagnostic Workflow

Santa Casa de Misericordia has selected Carestream to replace its legacy diagnostic workflow technology across all seven of its hospitals in Porto Alegre, the capital and largest city of the Brazilian state of Rio Grande do Sul.

American College of Cardiology Thanks Senators McConnell, Kaine for Efforts to Reduce Youth Tobacco...

On behalf of our patients, ACC members thank the Senators for their efforts to reduce youth tobacco use and stand ready to partner with them—and other members of Congress—to enact strong legislation establishing a federal age of 21 for the sale of all tobacco products.”

ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring Across 3 Countries

ResMed reports the average adherence to PAP (positive airway pressure), the gold standard for treating sleep apnea, is approximately 50 percent when using legacy technology with no cloud connectivity or remote monitoring capabilities.

Life Image and Bialogics Analytics Partner to Enable Provider Organizations to Optimize Operations, Interoperability

The Life Image and Bialogics partnership will streamline access to analytics of medical imaging in order to help provider organizations enhance operational and financial performance, and improve patient satisfaction.

MediSpin XL™ – Cutting-Edge High-Volume Electrospinning Production Platform for Medical Devices is Launched

The launch of the MediSpin XL™ platform marks a global breakthrough in the controlled large-scale production of well-defined scaffolds for implants and membranes using fibers ranging from nanometer up to micrometer scale.

Hemodialysis Vascular Grafts Market Size Worth $276.5 Million By 2025

Increasing number of patients suffering from chronic kidney diseases (CKD) and growing adoption of biological access products due to technological advancements in the field are some of the factors contributing to revenue growth. Higher number of renal impaired patients and limited availability of suitable kidney donors are promoting hemodialysis procedures in renal impaired patients, which in turn is expected to fuel the demand for vascular grafts over the forecast period.